ALCAM and ovarian cancer: Together with in vitro observations that inhibit MAN1A1 by kifunensine, a glycosylation inhibitor of MAN1A1, resulted in a shift between the cell surface and cytoplasmic fractions of ALCAM in ovarian cancer cells [13], it collectively indicates that the degree of glycosylation of ALCAM plays a key role in its function and clinical manifestation.